Quick Answer
MoonLake Immunotherapeutics reported Net Income of -$227.32 million for fiscal year 2025.
MoonLake Immunotherapeutics Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$227.32M | -91.1% |
| 2024 | -$118.94M | -230.3% |
| 2023 | -$36.01M | +27.9% |
| 2022 | -$49.97M | -1000.1% |
| 2021 | -$4.54M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$69.73M | -97.0% | -26.3% |
| June 30, 2025 | -$55.22M | -127.6% | -38.2% |
| March 31, 2025 | -$39.94M | -192.1% | -12.9% |
| September 30, 2024 | -$35.39M | -275.4% | -45.8% |
| June 30, 2024 | -$24.27M | -139.3% | -77.5% |
| March 31, 2024 | -$13.67M | -51.8% | -45.1% |
| September 30, 2023 | -$9.43M | +6.8% | +7.0% |
| June 30, 2023 | -$10.14M | +16.3% | -12.6% |
- MoonLake Immunotherapeutics showed a decrease of -91.1% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, MoonLake Immunotherapeutics’s net income has declined by 4904.1% (from -$4.54 million to -$227.32 million).
- The most recent figure is from MoonLake Immunotherapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: